The efficacy of oral treatment with chewable tablets containing afoxolaner 2.27% w/w (NexGard?, Merial, now part of Boehringer-Ingelheim) or 1.875% w/w of afoxolaner and 0.375% w/w milbemycin oxime (NexGard Spectra?, ...The efficacy of oral treatment with chewable tablets containing afoxolaner 2.27% w/w (NexGard?, Merial, now part of Boehringer-Ingelheim) or 1.875% w/w of afoxolaner and 0.375% w/w milbemycin oxime (NexGard Spectra?, Merial, now part of Boehringer-Ingelheim) was each assessed in eight dogs diagnosed with generalized demodicosis in this parallel group designed, blinded, randomized, single center negative controlled, efficacy study. Afoxolaner at the therapeutic dose (as close as possible to 2.5 mg/kg) was administered to Group 2 dogs, and afoxolaner (as close as possible to 2.5 mg/kg) with milbemycin oxime at 0.5 mg/kg was administered to Group 3 dogs on Days 0, 28 and 56. All dogs were observed once daily for general health starting on Day -7 until Day 84. All dogs were clinically examined on Days -7, -2, 14, 28, 42, 56, 70 and 84. Dogs were weighed on Days -7, -2, 27, 55, and 84. Live mite counts (based on five scrapings per dog and occasion) and clinical assessments, including photographic documentation, were performed on Days -2, 28, 56 and 84. Three monthly treatments with NexGard or NexGard Spectra against generalized demodicosis in dogs were highly effective resulting in a 99.9% and 100% efficacy against mites, respectively. After treatment with NexGard, only three live mites were recovered in five scrapings in one dog on Day 84. After treatment with NexGard Spectra, no mites were recovered in any scraping on any dogs in this group by Day 84. Both treatments resulted in a marked reduction of skin lesions and >90% hair-regrowth at three months after the initial treatment. Reduction of live mite counts was consistent with reduction in the extent and severity of the skin changes. Although the arithmetic mean mite numbers in the negative control group decreased slightly during the study, infection persisted in 7 of the 8 control dogs until Day 84. Both treatment groups of dogs showed a marked improvement of the associated dermatologic signs with steady improvement over the three-month treatment period.展开更多
The efficacy of afoxolaner (NexGard? and NexGard Spectra?, Boehringer-Ingelheim), administered once orally at the minimum recommended dose, was assessed in dogs experimentally infested with Ixodes hexagonus ticks. The...The efficacy of afoxolaner (NexGard? and NexGard Spectra?, Boehringer-Ingelheim), administered once orally at the minimum recommended dose, was assessed in dogs experimentally infested with Ixodes hexagonus ticks. The study was a blinded, negative controlled clinical efficacy study using a randomized block design. Twenty-four Beagle dogs, 12 females and 12 males were enrolled. Dogs were randomly allocated either to the negative control group, or to one of the two treated groups. Infestations were performed with 50 adult I. hexagonus ticks on Days-2, 7 and 28. On Day 0, dogs in groups 2 and 3 were treated with NexGard? (afoxolaner) or NexGard Spectra? (afoxolaner + milbemycin oxime), respectively. Tick counts were conducted 48 hours after treatment (Day 2) and 48 hours after each subsequent infestation (Days 9 and 30). In both treated groups, afoxolaner was 100% effective against existing infestations (p ? and NexGard Spectra? respectively. NexGard? and NexGard Spectra? chewable tablets administered once orally at the minimum recommended dose were highly effective against I. hexagonus infestations for the 4 weeks duration of the study.展开更多
The brown dog tick (Rhipicephalus sanguineus lato sensu) is the tick that most affects dogs worldwide and is therefore the main blood pathogen vector in dogs. The efficacy of afoxolaner 2.7 to 7.1 mg/kg NexGard<sup...The brown dog tick (Rhipicephalus sanguineus lato sensu) is the tick that most affects dogs worldwide and is therefore the main blood pathogen vector in dogs. The efficacy of afoxolaner 2.7 to 7.1 mg/kg NexGard<sup>®</sup> (group A) and afoxolaner plus milbemycin oxime 2.5 to 5.4 mg/kg and 0.5 to 1.1 mg/kg respectively NexGard Spectra<sup>®</sup> (Group B) against R. sanguineus, was evaluated in naturally infected sheltered dogs under high challenging conditions in four different areas of Colombia (Antioquia, Córdoba, Santander, and Meta). Tick counts (alive, dead, attached, and unattached) were performed on treated dogs, the average was calculated for the different areas to evaluate the efficacy of each treatment at six different times post-treatment (24 h, 48 h, 7 d, 14 d, 21 d, 30 d). None of the dogs showed adverse events related to the treatments. The average tick number pre-treatment was 68 in group A and 78.3 for group B indicating a strong natural infection of the dogs and their environment. Efficacy after 24 h against R. sanguineus was always above 90% with ≥97.4% for NexGard<sup>®</sup> and ≥93.7% for NexGard Spectra<sup>®</sup>. Consistent results were observed along all the observation periods with final efficacies (day 30) of ≥99.8% and 98.3% for NexGard<sup>®</sup> and NexGard Spectra<sup>®</sup>, respectively. In conclusion, both NexGard<sup>®</sup> and Nexgard Spectra<sup>®</sup> provided a curative effect and sustained efficacy against Rhipicephalus sanguineus for at least 30 days in highly contaminated shelter environments.展开更多
文摘The efficacy of oral treatment with chewable tablets containing afoxolaner 2.27% w/w (NexGard?, Merial, now part of Boehringer-Ingelheim) or 1.875% w/w of afoxolaner and 0.375% w/w milbemycin oxime (NexGard Spectra?, Merial, now part of Boehringer-Ingelheim) was each assessed in eight dogs diagnosed with generalized demodicosis in this parallel group designed, blinded, randomized, single center negative controlled, efficacy study. Afoxolaner at the therapeutic dose (as close as possible to 2.5 mg/kg) was administered to Group 2 dogs, and afoxolaner (as close as possible to 2.5 mg/kg) with milbemycin oxime at 0.5 mg/kg was administered to Group 3 dogs on Days 0, 28 and 56. All dogs were observed once daily for general health starting on Day -7 until Day 84. All dogs were clinically examined on Days -7, -2, 14, 28, 42, 56, 70 and 84. Dogs were weighed on Days -7, -2, 27, 55, and 84. Live mite counts (based on five scrapings per dog and occasion) and clinical assessments, including photographic documentation, were performed on Days -2, 28, 56 and 84. Three monthly treatments with NexGard or NexGard Spectra against generalized demodicosis in dogs were highly effective resulting in a 99.9% and 100% efficacy against mites, respectively. After treatment with NexGard, only three live mites were recovered in five scrapings in one dog on Day 84. After treatment with NexGard Spectra, no mites were recovered in any scraping on any dogs in this group by Day 84. Both treatments resulted in a marked reduction of skin lesions and >90% hair-regrowth at three months after the initial treatment. Reduction of live mite counts was consistent with reduction in the extent and severity of the skin changes. Although the arithmetic mean mite numbers in the negative control group decreased slightly during the study, infection persisted in 7 of the 8 control dogs until Day 84. Both treatment groups of dogs showed a marked improvement of the associated dermatologic signs with steady improvement over the three-month treatment period.
文摘The efficacy of afoxolaner (NexGard? and NexGard Spectra?, Boehringer-Ingelheim), administered once orally at the minimum recommended dose, was assessed in dogs experimentally infested with Ixodes hexagonus ticks. The study was a blinded, negative controlled clinical efficacy study using a randomized block design. Twenty-four Beagle dogs, 12 females and 12 males were enrolled. Dogs were randomly allocated either to the negative control group, or to one of the two treated groups. Infestations were performed with 50 adult I. hexagonus ticks on Days-2, 7 and 28. On Day 0, dogs in groups 2 and 3 were treated with NexGard? (afoxolaner) or NexGard Spectra? (afoxolaner + milbemycin oxime), respectively. Tick counts were conducted 48 hours after treatment (Day 2) and 48 hours after each subsequent infestation (Days 9 and 30). In both treated groups, afoxolaner was 100% effective against existing infestations (p ? and NexGard Spectra? respectively. NexGard? and NexGard Spectra? chewable tablets administered once orally at the minimum recommended dose were highly effective against I. hexagonus infestations for the 4 weeks duration of the study.
文摘The brown dog tick (Rhipicephalus sanguineus lato sensu) is the tick that most affects dogs worldwide and is therefore the main blood pathogen vector in dogs. The efficacy of afoxolaner 2.7 to 7.1 mg/kg NexGard<sup>®</sup> (group A) and afoxolaner plus milbemycin oxime 2.5 to 5.4 mg/kg and 0.5 to 1.1 mg/kg respectively NexGard Spectra<sup>®</sup> (Group B) against R. sanguineus, was evaluated in naturally infected sheltered dogs under high challenging conditions in four different areas of Colombia (Antioquia, Córdoba, Santander, and Meta). Tick counts (alive, dead, attached, and unattached) were performed on treated dogs, the average was calculated for the different areas to evaluate the efficacy of each treatment at six different times post-treatment (24 h, 48 h, 7 d, 14 d, 21 d, 30 d). None of the dogs showed adverse events related to the treatments. The average tick number pre-treatment was 68 in group A and 78.3 for group B indicating a strong natural infection of the dogs and their environment. Efficacy after 24 h against R. sanguineus was always above 90% with ≥97.4% for NexGard<sup>®</sup> and ≥93.7% for NexGard Spectra<sup>®</sup>. Consistent results were observed along all the observation periods with final efficacies (day 30) of ≥99.8% and 98.3% for NexGard<sup>®</sup> and NexGard Spectra<sup>®</sup>, respectively. In conclusion, both NexGard<sup>®</sup> and Nexgard Spectra<sup>®</sup> provided a curative effect and sustained efficacy against Rhipicephalus sanguineus for at least 30 days in highly contaminated shelter environments.
